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The purpose of this project is to determine how the treatment of Acute Heart Failure (AHF) patients 
within the Emergency Department affects short term outcomes such as hospital admission, the total 
length of hospitalization and the symptomatology. “Approximately three-quarters of all patients who 
are admitted for AHF are initially cared for in the Emergency Department” (Rodgers, 2006).  Although 
Emergency Department treatment plays a major role in the diagnosis of AHF patients, the optimal 
treatment for these patients is not defined. Further research into the impact that Emergency 
Department treatment has on the short term outcomes of AHF patients can define how to provide 
better care for these patients and how to manage hospital resources appropriately by administrating the 
optimal care. 
1.1 MQP Objectives 
The primary hypothesis of this investigation was the early (<1hour) use of vasodilators, and diuretics 
in acute heart failure patients will result in improved short term outcomes compared to patients given 
these medications later in their ED stay or not at all. This study was purely observational and all data 
collection was obtained through enrollment and observation of the care within the ED as well as from 
chart review. The first goal of this project was to enroll potential heart failure patients based upon the 
study criteria. After patients were enrolled, the goal was to collect pertinent information about their ED 
care and relate that information to their short term outcomes.  
  
2. Background 
2.1 The Heart 
The heart is an organ within the circulatory system whose function is to distribute blood to the 
tissues and cells of the body. The heart consists of four chambers including the left atrium and ventricle 
and the right atrium and ventricle. The heart pumps oxygenated blood out of the left ventricle through 
the aorta and into the arteries. The left ventricle is the main pumping chamber and must have enough 
force to provide blood to all of the tissues in the body; therefore it is stronger than the other chambers. 
The arteries, which carry the blood out from the left ventricle, break into smaller vessels called 
arterioles which eventually meet up with venuoles (the smaller branches of veins). The areas in which 
these two vessels meet and connect are called capillaries. The walls of the capillaries are very thin and 
allow for diffusion and exchange of deoxygenated and oxygenated blood (Texas Heart Institute Heart 
Information Center, 2011). 
 The once the blood has been deoxygenated within the capillaries, if flows back to the heart 
through veins. The veins carry the blood through the vena cava and back into the right atrium of the 
heart. The blood then passes through the tricuspid valve and into the right ventricle.  The right ventricle 
pumps the blood through the pulmonary artery and through the lungs where the blood is oxygenated. 
After oxygenation, the blood returns through the pulmonary vein, into the left atrium to the left 
ventricle where the process is repeated once again (Texas Heart Institute Heart Information Center, 
2011). The anatomy of the heart is shown in Figure 1. Understanding the anatomy of the heart allows 
for a more educated approach in the study of heart failure.  
 
Figure 1: Anatomy of the Heart (What is the Heart, 2009) 
The pumping of blood throughout the body is based open the contraction of the heart. 
However, the contraction of the heart could not occur without electrical signaling. The heart receives an 
electrical signal which begins in the sinoatrial (SA) node which is located in the right atrium. The signal 
travels across the cells in the right atrium and then into the left atrium. This electrical signal causes the 
atria to contract and the blood is pushed into the ventricles. As this is happening, the electrical signal 
reaches the atriventricular (AV) node in the septum near the tricuspid valve. From here the signal moves 
along the Purkinje fibers, which are fibers that stretch across the left and right ventricles. This causes the 
ventricles to contract, forcing the blood into the next chamber or out of the heart and into the body 
(Bryg, 2009). 
2.2 Heart Failure 
2.2.1 Introduction 
Heart failure is a condition in which the heart has lost the ability to provide an adequate amount 
of blood to the rest of the body. As a result the organs throughout the body are not receiving enough 
oxygen to properly function. Heart failure symptoms have been described in ancient texts (Katz, 2012), 
even though they were not understood. Today, heart failure is the leading cause of hospital admission in 
people over the age of 65 with 1 million admissions per year (Centers for Disease Control and 
Prevention, 2011). In the United States there are more than 5 million individuals diagnosed with heart 
failure and that number is consistently rising with about a half million new cases each year.  Heart failure 
becomes increasingly more common with ages affecting 1% of people age 50 and over, 5% of people 75 
years and older and 25% of people aged 85 years or older (Centers for Disease Control and Prevention, 





Figure 2: Age specific death rate for CHF (Centers for Disease Control and Prevention, 1994)  
There are many different classifications of heart failure which stem from the type of malfunction 
within the heart. This project is specifically interested in congestive heart failure, which is characterized 
by a buildup of fluid within the body’s tissues. Congestive heart failure is a condition where the pumping 
action of the heart becomes less and less powerful over time (American Heart Association, 2011). 
Therefore, the blood cannot move properly throughout the circulatory system and begins to back up 
into the tissues of the body. This back up causes an increase in blood pressure which also forces the fluid 
within the vessels into the surrounding tissue.  
Although heart failure is extremely common, the symptoms can easily be mistaken for other 
diseases or disorders making the condition difficult to diagnose. Because the symptoms are broad and 
overlap with other diseases heart failure is commonly misdiagnosed initially. Therefore, the treatment 
given to heart failure patients tends to vary from patient to patient. However, the initial treatments 
given to these patients can have strong consequences on their short term outcomes and overall 
prognosis.  
2.2.2. Heart Failure Classification 
 There are a variety of reasons for the development of heart failure, allowing the condition to be 
classified in a number of ways. The first classification of heart failure is into congestive and non-
congestive categories. Congestive heart failure, as described above, is when fluid builds up in the body’s 
tissues. The buildup of fluid is called edema and it is the main factor in determining whether a patient 
has congestive vs. non-congestive heart failure (Darling, 2011).  When the left side of the heart is the 
main cause of failure, the fluid will back up into the lungs causing a condition called pulmonary edema. 
When the right side of the heart is the main cause of failure the fluid backs up into the body’s tissues, 
most commonly in the legs and feet. As this condition worsens, the fluid backup will move up the legs 
and can even begin to build up within the abdomen (Darling, 2011). 
 Congestive heart failure can also be classified as systolic heart failure and diastolic heart failure. 
Systolic heart failure is characterized by the weakening of the pumping action of the heart. Classification 
of systolic heart failure is based upon measurement of the hearts ejection fraction, which is the portion 
of blood that is pumped out of a filled ventricle as a result of a heartbeat. A normal ejection fraction is 
usually within the range of 55%- 70% and values less than these usually represent a patient with systolic 
heart failure. Diastolic heart failure can be characterized by a stiff heart which is less compliant when it 
is filling with blood. In diastolic heart failure the pumping action of the heart is not affected, however, 
the stiffness prevents blood from reentering the heart and causes fluid to back up into the lungs (Mayo 
Clinic, 2011).  
2.2.3 Symptoms 
Heart failure patients can present with a variety of different symptoms, many of which will 
overlap with other diseases. However, there are three main categories of heart failure symptoms 
consisting of exercise intolerance, shortness of breath and fluid retention and swelling. During the early 
stages of heart failure, individuals will begin to experience difficultly exercising or even performing 
normal physical activity that they had been comfortable with in the past. The heart is not able to pump 
enough blood to provide the oxygen and other nutrients necessary for the body to function properly. 
When this is true, individuals will become short of breath while doing these activities and rest is needed 
to return the body to its comfortable state (Mayo Clinic, 2011).  
As a patient’s heart failure becomes more advanced, shortness of breath will become more 
regular and more severe. Dyspnea (shortness of breath) most commonly occurs in heart failure patients 
while they are active throughout the day or while they are lying down. If there is fluid buildup into the 
lungs, the fluid will primarily stay at the base of the lung while an individual is standing due to gravity. 
However, when a person lays down the fluid will disperse and interfere with oxygen getting into the 
blood making breathing more difficult. Patients will also experience paroxysmal nocturnal dyspnea 
meaning they will awaken at night with shortness of breath. Most often this symptom can be relieved by 
sitting upright or standing (A.D.A.M Medical Encyclopedia, 2011).  
 Heart failure patients will often experience fluid retention and swelling. As noted previously, the 
heart’s inefficiency can cause fluid to back up into the lungs, known as pulmonary edema, or to black up 
into the extremities causing peripheral edema. Peripheral edema is most common among heart failure 
patients at the end of the day after prolonged periods of sitting and standing. Heart failure will cause a 
specific type of edema called pitting edema. Pitting edema is recognized by pressing a finger to the 
swollen area. If a fingerprint remains on the skin this is pitting edema. Non-pitting edema is not caused 
by heart failure and should not be considered a symptom. Patients diagnosed with heart failure typically 
undergo daily weight checks because the amount of fluid retention correlates with shortness of breath 
(Darling, 2011).  
Other symptoms of heart failure include: fatigue, weakness, irregular heartbeat, persistent 
cough, swelling in the abdomen, lack of appetite, nausea and difficulty concentrating. These symptoms 
often are not all present and can be attributed to many causes other that heart failure, making it 
difficult to diagnose (Mayo Clinic, 2011). 
2.2.4 Causes of Heart Failure 
Congestive heart failure is a condition which is caused by an underlying heart or blood vessel 
problem. Heart failure patients typically have numerous underlying problems which cause the heart to 
weaken over time. Reduction in the heart’s pumping efficiency can be due to damage or overloading of 
the heart muscle.  Causes of damage or overloading include coronary artery disease, damaged heart 
valves, high blood pressure, arrhythmias and heart muscle damage (What is the Heart, 2009).  
Coronary artery disease is a result of the narrowing of small blood vessels that supply blood and 
oxygen to the heart.  Decreasing the amount of blood flow to the heart muscle deprives it of blood 
which in turn, weakens the heart. Narrowed arteries are often caused by atherosclerosis, which is the 
buildup of plaque.  If the plaque in these arteries ruptures or releases from the wall it can cause a clot 
and block blood flow causing a heart attack. Patients with coronary artery disease are at a much greater 
risk for heart failure. 
Another common cause of heart failure is damaged heart valves. Specific heart valve conditions 
include valvular stenosis which is when the valve opening is smaller than normal due to fused leaflets. 
This causes the heart to be overworked because it must pump harder to push the blood through this 
valve. Leaky valves occur when the valves do not close tightly and therefore allow blood to leak 
backwards and as this condition worsens the heart must work harder to overcome this blood loss or the 
body will receive less blood. Both of these valve conditions put patients at a greater risk for heart failure 
and if the heart becomes overworked, it will typically result in decreased efficiency (What is the Heart, 
2009) 
High blood pressure is not typically a cause heart failure; however it can be a contributing factor 
when experienced along with other risk factors. Blood pressure is the force of blood pumped by the 
heart through the arteries. When the blood pressure is high the heart is working harder to contract 
more quickly and more forcefully. The heart muscle can become thicker due to the extra work resulting 
in the heart pumping less efficiently. 
Prolonged arrhythmias eventually lead to heart damage and therefore they present a risk factor. 
An arrhythmia is an abnormal heart beat (The San Diego Cardiac Center, 2010). Certain arrhythmias can 
cause the heart muscle to work harder and can lead to less production. Overtime the heart will weaken 
creating the potential for failure. Along with arrhythmias, muscle damage can cause the heart to 
weaken. The blockage of blood vessels that supply the heart muscle can lead to a heart attack. Heart 
attacks cause damage to the tissue within the heart muscle and can also cause scar tissue formation. As 
a result of a heart attack the heart is weakened and may not be capable of pumping enough blood to 
support the body. Diseased heart muscle that results from an unknown cause is known as idiopathic 
cardiomyopathy, another risk factor for heart failure due to muscle weakening (Mayo Clinic, 2011).  
2.2.5 Diagnosis of Heart Failure 
Investigation into a patient’s medical history is an important step in diagnosing heart failure. 
Doctors will look for these different underlying diseases and risk factors in combination with the 
patient’s present symptoms to develop a diagnosis. However, it is still very difficult to distinguish heart 
failure from similar illnesses that cause breathing difficulties such as bronchitis, pneumonia, emphysema 
and asthma. A typical differential of a potential heart failure patient can be seen below.  
                                                      
 
Figure 3: Typical Differential of Patients Presenting with Possible Heart Failure (Darling, 2011)  
 To help doctors diagnose heart failure, clinical tests can be performed on the patient. Common 
tests may range from minimally invasive chest x-rays, electrocardiograms blood tests, stress tests and 
observation to more invasive echocardiograms and (Mayo Clinic, 2011).  
Patients with suspected heart failure usually undergo a chest x-ray to help determine the 
presence of fluid in the lungs.  The presence of fluid hints towards a heart failure diagnosis. Doctors will 
also examine the chest x-ray for heart size. The heart is usually enlarged in CHF patients and this may be 
visible on the chest x-ray. Close examination of the x-ray may also unveil abnormalities in the patient’s 
heart valves or other structures.  
Along with a chest x-ray, blood tests can be performed to assist in diagnosing heart failure. 
Blood tests are only minimally invasive and therefore they are frequently used in diagnosis. Common 
blood tests measure kidney function, thyroid function and the level of brain natriuretic peptide (BNP).  
The most commonly used result for the diagnosis of heart failure is the BNP level. Brain natriuretic 
peptide is an endogenous hormone released into the blood from stretched ventricles. When the heart is 
overworked over a long period of time, it will cause an increased level of BNP, and usually a level 
>400pg/mL is suggestive of heart failure.  The BNP level is a good screening test and the levels usually 
correlate with the severity of the patient’s heart failure (Rodgers, 2006). 
A stress test and observation of the patient is sometimes helpful in determining if heart failure is 
an appropriate diagnosis.  A stress test can show the way in which the patient’s body responds to 
exertion. Because heart failure patients experience shortness of breath during physical exertion, this can 
be a very simple but significant test. In addition, many heart failure patients will present with a third 
beat called an S3 beat. This is a dull and low-pitched sound heard when examining the chest. This sound 
is caused by the oscillation of blood in the ventricles or by tensing of the chordae tendineae during rapid 
ventricular filling. By listening to the patient’s heart rhythm, the doctor can determine if the patient has 
this additional beat. Along with listening to their heart rhythm, doctors will conduct a JVP measurement 
which is seen in Figure 4. 
 
Figure 4: Diagram of a JVP measurement 
This measurement is obtained by sitting patients up to 45 degrees and measuring the elevation 
of neck veins above the sternal angle. Once the elevation is measure 5cm are added because the right 
atrium is 5cm below the sternal angle (Rodgers, 2006).The normal measurement is around 8cm however 
in patients with CHF their pressure is much higher and therefore they cannot raise their neck as much.  
Although these minimally invasive tests can be helpful in the diagnosis of heart failure, 
additional tests including echocardiograms and electrocardiograms may be performed. An 
echocardiogram is a type of ultrasound test that bounces sound waves off different parts of the heart 
which allow a moving picture of the heart.  In heart failure diagnosis the main result of an 
echocardiogram is the ejection fraction, which shows the fraction of blood pumped out of the ventricles 
with each heartbeat. A normal ejection fraction is usually between 50-70% and values lower than the 
normal may suggest heart failure.  Electrocardiograms (EKG’s) are also minimally invasive and can be 
used to test the electrical activity of the heart. This may show an underlying condition that presents a 
risk for future heart failure. Typically an accurate diagnosis of heart failure cannot be made without a 
combination of these strategies (Rodgers, 2006). 
2.2.6 Heart Failure Treatment  
Once heart failure has been diagnosed, there are many different treatments to alleviate the 
symptoms and surgeries to correct the damage caused by this condition.  Many medications including 
diuretics, vasodilators, nitrates, inotropes, digitalis, beta- blockers, natriuretic peptides and nitroglycerin 
can all be used to treat patients diagnosed with heart failure.  
Diuretics are given to about 90% of heart failure patients to keep fluid from building up in the 
body (Darling, 2011). Diuretics cause the kidneys to remove excess salt and accompanying water from 
the blood stream. This results in a decreased amount of blood volume (blood pressure) in circulation 
making it easier for blood to be pumped throughout the body. There are three types of diuretics 
commonly used to treat heart failure. Thiazides are used to treat high blood pressure by reducing the 
amount of sodium and water and dilating the blood vessels to lower the patient’s blood pressure. 
Potassium-sparing diuretics reduce the amount of water in the body; however, they do not cause the 
potassium levels in the body to drop. The third type of diuretic used is loop-acting diuretics which cause 
the kidneys to output an increased amount of urine.   By doing so the amount of water in the body is 
decreased and blood pressure is lower. Although they are commonly administered and do improve 
symptoms, their efficacy in improving the short term outcomes in CHF patients has not been 
established. The main concerns in administering diuretics exist around their potential to activate the 
renin-angiotensin aldosterone system and the sympathetic nervous system. The activations of these 
systems may raise the ventricular filling pressures and can lead to reduced renal function (Mayo Clinic, 
2011). 
A more specific category of medication used to treat heart failure is vasodilators. Common 
vasodilators include ACE inhibitors, angiotensin II receptor blockers, beta-blockers and nitrates. Overall 
the goal of vasodilators is to enlarge the arterioles, which helps to relieve the systolic work that must be 
performed by the left ventricle. By reducing the work load of the left ventricle the heart can more easily 
pump blood throughout the body (Darling, 2011).   
The most common type of vasodilator used to treat heart failure is ACE inhibitors. These 
medications block the production of angiotensin II which is a vasoconstrictor molecule. Angiotensin II 
acts as an endocrine and autocrine hormone and it increases blood pressure by stimulating Gq protein 
in smooth muscle cells. Angiotensin II causes an increased workload for the left ventricle and it is 
increased in heart failure patients. ACE inhibitors work by blocking the conversion of angiotensin I to 
angiotensin II causing reduced production of angiotensin II.  This type of medication improves the 
immediate symptoms of heart failure patients but they also help to prolong the lives of heart failure 
patients by slowing the progression of heart damage. A similar type of medication is an Angiotensin II 
receptor blocker (ARB). ARBs work by preventing the effect of angiotensin by preventing the molecule 
from binding to its receptor.  These are only prescribed when the patient is unable to tolerate the ACE 
inhibitor side effects (Rodgers, 2006).  
ACE inhibitors and ARBs are arterial vasodilators, while nitrates are venous vasodilators.  
However, these vasodilators are not as strong or effective as the arterial vasodilators. They are often 
used in combination with the arterial vasodilators for increased symptom relief.  Nitrates are also 
commonly used in conjunction with Hydralazine which is a smooth muscle arterial vasodilator. This type 
of medication is prescribed most often in African Americans or patients with poor kidney function 
(A.D.A.M Medical Encyclopedia, 2011). 
Beta- blockers can be given to heart failure patients and their long term use may help in 
gradually improving the systolic function of the left ventricle. Beta-blockers work to slow down the heart 
rate, lower the blood pressure and therefore lessen the workload of the left ventricle. These drugs work 
by blocking the action of norepinephrine and epinephrine on the heart muscle. Norepinephrine and 
epinephrine are produced by the sympathetic nervous system however; they can be toxic to the heart at 
high doses over a long period of time. Overall the consistent use of beta blockers can help prolong the 
life of heart failure patients.  
A drug, B- type natriuretic peptide (BNP) is a molecule that is produced by the heart muscle and 
is produced in excess in heart failure patients. However, it has been determined that giving additional 
BNP intravenously can lower the pressure in the lung and can function as a mild diuretic. This causes the 
water within the lungs to be removed and excreted through the kidneys, resulting in the pulmonary 
congestion relief. This usually prescribed to patients who experience a sudden onset of heart failure 
symptoms or their condition worsens very quickly. Therefore it is an important drug in the emergency 
room treatment of heart failure (Mayo Clinic, 2011).  
Similar to natriuretic peptides, nitroglycerin is commonly used to treat heart failure patients 
who experience chest pain. This drug can also be used as a preventative measure for heart failure 
patients who are about to undergo physical activity. This drug works by relaxing the blood vessels so 
that the heard does not need to work as hard and therefore it can use less oxygen. Nitroglycerin is 
different from the other drugs in that the capsules are long acting, however they cannot be used to 
relieve chest pain once it has begun. Therefore it is a strictly preventative medication.   
If the treatment of heart failure symptoms is not successful, surgery may be an option. There 
are numerous surgeries that can alleviate the effects of heart failure. Coronary bypass surgery is used to 
bypass a blockage that could be created from the narrowed arteries and arthrosclerosis. Heart valve 
repair or replacement is another common surgery. Implantable cardioverter-defibrillators and 
pacemakers monitor the heart beat and will send an electric shock if the device detects an irregular 
heartbeat. If the heart failure becomes severe enough a left ventricular assist device (LVAD) can be 
implanted to pump the heart and relieve the work of the heart. The last most serious treatment is a 
heart transplant which is only done in the most severe cases (Mayo Clinic, 2011).  
Doctors will prescribe the appropriate type of treatment needed after their assessment of the 
patient’s symptoms and the underlying cause of their condition. Some of these medications are used in 
conjunction to improve their effectiveness. There is not set treatment plan for a patient presenting with 
heart failure, but many algorithms for treatment have been proposed.  Figure 5 displays a proposed 
algorithm for the treatment of a patient who potentially has heart failure. (Collins, 2007) This algorithm 
is used as a reference for the residents and doctors within the emergency room, however they are not 
official guidelines that they must follow.   
 
Figure 5: Proposed treatment algorithm for a patient presenting with suspected heart failure (Collins, 2007)  
A similar algorithm is shown in Figure 6 except this algorithm begins with patients who enter the 
emergency room with shortness of breath as their chief complaint.  
 
 Figure 6: Proposed treatment algorithm for patient presenting with dyspnea (Collins, 2007)  
These algorithms serve as treatment guidelines; however they have not been studied in 
relationship to the short term outcomes of patients. These algorithms become even more specific if they 
are related to the presenting blood pressure which is classified as normotensive (100-140mm Hg) 
hypertensive (>140mm Hg) and hypotensive (<90mm Hg).  Figure 7 shows the proposed algorithm for 
patients diagnosed with heart failure and presenting with a hypotensive blood pressure.  
 
Figure 7: Proposed treatment algorithm with patients diagnosed with hypotensive heart failure (Collins, 2007)  
As you can see from Figure 7, the treatment of heart failure is much more specific when the plan 
is based upon the presenting blood pressure. In this plan, there are fewer decisions to be made than 
when blood pressure is not integrated into the algorithm from the beginning. The proposed treatment 
algorithm for hypertensive patients can be seen in Figure 8.  
 
Figure 8: Proposed treatment algorithm for patients diagnosed with hypertensive heart failure (Collins, 2007)  
In Figure 8 there are more considerations to be made than in the proposed algorithm for a 
hypotensive patient, which was presented in Figure 8. The same trend is seen below with even more 
decisions being necessary when the patient presents with a normotensive blood pressure as seen in 
Figure 9.  
 
Figure 9: Proposed treatment algorithm for patients diagnosed with normotensive heart failure (Collins, 2007)  
 Overall these algorithms provide insight into the decision making process that a doctor 
establishes when a patient presents with heart failure. As shown in these figures, the course of action 
becomes more specific when the presenting blood pressure is used to customize the treatment.  
Although these are good methods for deciding upon the treatment of a heart failure patients there is 
still a great deal of change from one patient to another with many treatment possibilities available. If 
these algorithms can be improved based on outcome data, patients may have a more streamlined 
course of treatment which could result in an improved prognosis for heart failure patients.  
2.2.7 Prognosis 
The prognosis for patients with heart failure patients is fairly poor. Patients with severe heart 
failure symptoms have the worst prognosis with 50% of patients dying within a year of diagnosis. This 
statistic decreases in patients with less severe symptoms with 50% of patients dying within 3 to 4 years 
of diagnosis (American Heart Association, 2011). The main determination in the prognosis of a patient is 
the function of their left ventricle which can be determined by their ejection fraction.  The lower that 
the ejection fraction becomes in a patient, the worse prognosis becomes (American Heart Association, 
2011). 
 Many patients with heart failure die suddenly from ventricular arrhythmias; however the 
medications used to treat heart failure have been consistently improving providing a better outlook for 
heart failure patients. The uses of beta-blocker and ACE inhibitors have now been shown to cause a 
decrease in mortality rates among heart failure patients. With this being said, 10% of heart failure 
patients die per year (Centers of Disease Control and Prevention, 1994). It is important that the 
treatment of these patients improve so that their lifespans can be prolonged and the condition of life 
can improve for heart failure patients as well.  Improved treatment plans are also important to relieve 
the burden that these patients place upon the hospital system.  
2.3 Heart Failure’s Burden on Hospitals 
 Along with improving the overall prognosis of heart failure patients, extended research into the 
treatment of heart failure can relieve some of the burden placed on hospital by this condition. Heart 
failure has a very high mortality rate and is the end stage of cardiac disease.  Eighty percent of men   
seventy percent of women above the age of 65 who have heart failure will die within 8 years. Along with 
the severity of the disease, heart failure was the cause of 3,390,000 hospital visits in 2006. The number 
of emergency room visits due to heart failure places a severe economic burden upon hospitals. These 
patients are often admitted into the ICU or inpatient care, utilizing even more hospital resources. In 
2009 it is estimated that 37.2 billion dollars was spent on heart failure (Centers for Disease Control and 
Prevention, 2011).  Of the total 37.3 billion approximately 20.1 billion relates to hospital costs alone. 
These costs are only going to rise in the future with a growing percent of the population entering the 
above 65 age range (Peacock, 2004).To better utilize the hospitals resources, investigation on how to 
optimize emergency room treatment of heart failure is essential. Optimal emergency room treatment 
will result in a shortened length of stays and fewer admissions. To optimize the care given to heart 
failure patients a clinic trial was proposed and initiated.  
2.4 Clinical Trials 
 A clinical trial is a biomedical or health-related research study that uses human beings as the 
test subjects. The trial must follow a pre-defined protocol. There are two types of trials that can be 
done, interventional and observational. Interventional studies involve assigning subjects to a treatment 
or some other intervention, and then the outcomes are measured. Observational studies are when the 
subjects are observed and the outcomes are merely observed and analyzed by the investigators. An 
observational study does not involve changing the treatment of the patient in anyway (Clinicaltrials.gov, 
2011).  Since observational studies are not randomized they can have certain biases that alter the results 
of the study.  
2.4.1 Purpose of clinical trials 
The purpose of clinical trials is to better the health care field. Different aspects of health are 
studied which can help doctors and other health professionals know how to best treat individuals with 
these problems. These studies can also help a hospital or health care facility run more effectively.  
2.4.2 Clinical Trial Procedures  
Once the trial has been approved, by the hospitals institutional review board, the next step is 
recruiting patients. In order for the subject to be admitted to the trial they must provide informed 
consent. This is done by explaining the study to the patients in plain English and ensuring that they fully 
understand the study. IF the patient does not speak English, an attempt can be made to obtain consent 
from a family member. However, if consent cannot be obtained from a family member, no translator 
can be provided so that patient was not enrolled. They must be informed of any risk or benefit to them. 
They also need to be informed that at any time they may withdraw from the study. Then the subject can 
be asked if they would be willing to be a part of the study. From here the patient gives their consent and 
signs a consent form as well as whatever other forms are needed for the hospital. Often a HIPPA (Health 
Insurance Portability and Accountability Act) form also needs to be signed to obtain the patients clinical 
records (Clinicaltrials.gov, 2011).  
2.4.3 History and Ethical Considerations  
 The term clinical trials may be relatively new but the idea has been around for hundreds of 
years. Starting in the 1700’s there were experiments that used untreated control groups to study the 
effects of certain drugs. Dating back to the 1800s the United States completed clinical trials relating to 
smallpox. However, Germany experiments that occurred in Nuremberg brought forward many changes 
to the ways clinical trials were done (Meinert, 2012). The Nazis performed medical trials and procedures 
on their prisoners that were extremely unethical. Because of these extremely unethical acts at 
Nuremberg there was a code termed the Nuremburg code that is essentially what medical ethics were 
built on. The code set the boundaries for what is acceptable and what is not in the medical world.  It 
dictates that clinical trials are conducted in a manner that can only benefit people rather than harming 
them (Nuremberg). 
The Nuremberg code adopted in the 1950’s brought several other advances for clinical trials. In 
1966 Institutional Review Boards (IRBs) were mandated, that would be responsible for approving all 
trials before they could be started. To this day before clinical trials can be initiated they must be 
reviewed and approved by an Institutional Review Board (IRB). Approval is based on review of 
information provided by the researcher and describing the details of the study and exactly how the 
patients will be involved in the trial (Meinert, 2012). 
2.5 Previous Clinical Trials on Heart Failure: The Framingham Study 
Previous studies investigating heart failure have been done. One such study, The Framingham 
Heart Study was conducted to identify the common factors that contribute to cardiovascular disease by 
following its development over a long period of time following a large group of participants who had not 
yet developed overt symptoms. Overall the original study enrolled 5,209 men and women who fell into 
the 30-62 age range and it collected data about their lifestyle and medical history (Arruda, 2011). 
Eventually the study began enrolling patients outside of the original Framingham resident participants.  
The study enrolled patients from three generations beginning with the original Framingham 
residents, and two generations of participants recruited outside of Framingham. The study reviews the 
patients’ medical history, conducts a physical examination and conducts laboratory tests every two 
years. The collection of this information has allowed for the identification of the risk factors for 
cardiovascular disease. These risk factors have been compiled into The Framingham Criteria. The criteria 
are shown in Figure 10 and will serve as the guideline for this project’s inclusion and exclusion criteria.   
  
 
Figure 10: Criteria developed based upon the conclusions from the Framingham study (Arruda, 2011) 
The Framingham criteria are the most accepted way of diagnosing heart failure. The diagnosis 
incorporates major criteria and minor criteria. If a patient has two or more major criteria or one major 
and 2 or more minor criteria, they are considered highly likely to have heart failure.  The major and 
minor criteria are both shown in Figure 10.  
Heart failure does not have a definitive way of being diagnosed at this point in time. Because of 
this Dr. Chad Darling has embarked on an observational study to determine the best method of 
treatment that will lead to short hospitals stays for individuals with heart failure. This study is important 
because of the positive implications for the patients as well as the hospital. With shorter hospital stays 
the patients can live their lives more outside of the hospital and spend less money on medical bills. The 
shorter hospital stays will open up more rooms for other patients, and will take some of the stress off of 
the nurses and doctors. To complete this study there is a certain methodology that must be followed. 
3. Methodology  
3.1 Clinical methods  
During this investigation protocol outlined in the IRB form, completed by Chad Darling, was 
followed. Patients presenting to the Emergency Department with a primary complaint that included any 
of the symptoms of heart failure (shortness of breath, chest pain, edema, and sometimes congestive 
heart failure) were considered potential candidates for the study. Their medical records were accessed 
to determine if they had a history of heart failure. If they had a history of heart failure or if they did not 
have a history but the symptoms could still indicate heart failure they continued to be considered for 
enrollment. The final inclusion and exclusion criteria that were used to ensure the integrity of the trial 
were:  
Inclusion Criteria:  
 Male or female 18 years of age or older 
 Presenting to ED with dyspnea concerning for acute heart failure 
Exclusion Criteria 
 Final (hospital determined) primary or secondary diagnosis that is not heart failure  as 
determined by the Framingham Criteria for HF  
 AHF occurring in the setting of acute myocardial infarction 
 Dyspnea clearly due to alternative diagnoses (Asthma)  
 Inability to provide informed consent (e.g. mentally incapacitated) 
 Pregnancy 
Once a patient that met these criteria and had been examined by a doctor the next step was to 
ask the doctor what he/she believed the patient was suffering from. If the doctor believed it was heart 
failure the patient was approached. If the doctor did not believe it was heart failure but the medical 
history and symptoms all supported heart failure as a probable diagnosis the patient was still 
approached.  
Approaching the patient was done in a way as to not scare or overwhelm them. The patient was 
told about the study ensuring that they understand that it was strictly observational and that there was 
no harm or benefit to them, only the potential to help future patients. The patients were told it was a 
study involving heart failure but that did not necessarily mean that they would be diagnosed with heart 
failure that day. Researchers are not doctors so giving a diagnosis to the patients was not appropriate. 
Once the patient had received all the necessary information they were asked if they would be willing to 
participate in the trial. They were then required to sign a consent form and a medical records release 
form. 
Once a patient had signed all the appropriate forms they were asked to complete a series of 
wellness scales. The first scale was the global well-being scale. This scale was from zero to 100; with zero 
being the worst you’ve ever felt and 100 being the best you’ve ever felt. The patient was asked orally to 
compare how they feel at that moment with how they feel on a normal day (before the onset of 
symptoms). The patient was then asked to draw a line through the scale at the appropriate location 
corresponding to how they felt. The next two scales involve shortness of breath. The first of the two was 
similar to the global well-being scale using the same scoring system; with zero being the worst you’ve 
ever felt and 100 being the best you’ve ever felt. Again the patient was asked to compare how they felt 
at that instance to their normal day and then asked to draw a line through the scale at the 
corresponding location. The last scale was a shortness of breath scale with several markers and faces for 
markedly better, mildly better, mildly worse and markedly worse. The patient was asked to score their 
shortness of breath based on when they came in to the emergency room. The patient was asked to 
check the box that best describes their state.  
After all the scales were filled out the patient was asked for their height and weight. They were 
then thanked and the researcher left the room. In an hour or two the researcher returned to the room 
to ask the patient to fill out the three scales again. During this second visit the patient was asked if they 
have taken in any fluids as well as if they have urinated. If the patient was admitted they were visited 
the next day and asked to fill out the same three scales for the last time.  In addition to the scales at the 
third hour the patient is also asked to speak about how satisfied they are with the care they received in 
the emergency room. The patient was asked two multiple choice questions about the quality of care and 
then the patient was asked open-endedly what they liked or what they would improve.  
 While the patient was still in the emergency department their nursing and doctor’s notes were 
copied to keep in the record. If there were any electrocardiograms (EKG’s) these were also copied. The 
patient’s medicine list was also obtained from either the patient or the nurse while the patients were in 
the emergency room. Using this information a sheet with all the pertinent information was filled out. 
This information consists of: blood pressure, heart rate, respiratory rate and percent of oxygen 
saturation. These are taken every hour for three hours as well as the initial reading, the triage reading. 
The form used for the data collection can be seen in Appendix E.     
The chart review process was the last step of the methodology. The first step was to measure 
the patient scales with a ruler. Figure 11 shows an example of the global well-being scale. 
 
Figure 11: Global Well Being Scale 
(U.S. National Institutes of Health, 2007) (Centers for Disease Control and Prevention, 2011) 
(Katz, 2008; Mayo Foundation for Medication Education adn Research, 2011; Peacick, 2002; Collins, 
2005)The entire scale was set to equal 100mm. The patients were asked to draw a line through the scale 
that relates to their well-being. The distance from the 0 point of the scale to the line marked by the 
patients was measured and recorded in millimeters. The doctor’s final diagnosis was determined and 
with this it is decided if the patient is ruled in or ruled out. The doctor’s final primary, secondary or 
tertiary diagnosis must have been heart failure in order to use the patient’s data.  Once this was done all 
the information gathered while the patient was in the emergency room was compiled in the RedCap 
system online. Redcap is a website which allows projects to be established. All of the information 
gathered from enrolling patients and reviewing charts was entered into this online system. Once 
completed, the results were exported from this website into excel and statistical analysis was performed 
on the data.  
3.2 Methods of Analysis 
 The main source of analysis for the experiments was graphical representations of data as well as 
analysis of variances (ANOVA). The ANOVAs were used to see if the data had any sort of statistical 
relevance. The ANOVAs showed if there was a significant difference between patient groups given 
medicine and those not given medicine. In many cases the sample size is too small to see any statistical 
significance, because the study had only been in progress for a few months. With a small sample size it 
was not expected that the data would have any sort of statistical significance.  The graphs were used to 
show trends where the statistics did not support the hypothesis. These graphs were generated using the 
GraphPad program bar graphs. The graphs allowed for comparison between different groups that the 
ANOVA could not be as specific with, and allowed for the visualization of trends. 
 Other statistics that were done with the data was means, medians and standard deviations. 
These allowed for a general overview of the average heart failure patient, as well as an understanding of 
how much heart failure patients can vary from one another (Standard Deviation). Medians were done as 
well because the standard deviations were often very large, and the medians provided a better view of 
the average heart failure patient.   
4. Results and Discussion  
Specifically, the goal of this study was to determine whether the early use of vasodilators and 
diuretics in acute heart failure patients would results in improved short term outcomes. Data was 
collected on 38 patients who fit the Framingham criteria. This data was analyzed to see if the 
hypotheses were validated.   
4.1 Trial Demographics 
Based upon the enrollment criteria, 38 patients were enrolled into this clinical trial. These patients 
were then determined to be “rule in” or “rule outs” based upon the Framingham Criteria during the 
chart review process.  




Total 41 Triage Systolic BP Triage HR Triage RR 
Enrolled 30 Mean 134.8378 Mean 84.081 Mean 21.7027 
Male 
Enrolled 
21 STD 25.18654 STD 22.447 STD 4.624001 
Female 
Enrolled 
9 Median 135.5 Median 80 Median 21 
 
The total number of enrolled patients was 41, with 11 patients that were ultimately determined 
to be ruled out of the trial. .This information shows that the inclusion and exclusion criteria for the study 
are effective. This information can be useful for future doctors who wish to enroll patients presenting 
with heart failure.  
 The patients sex was recorded and it was determined that 21 were males and 9 were females. 
More males presenting with heart failure is consistent with national averages. This is useful information 
for the principal investigator because it may change future decisions about enrollment. For example, it 
may be decided to only include male patients because they are much more prevalent and therefore the 
study would be more efficient in seeking out potential heart failure patients.  This study is interested in 
more than just males though, so this would not be necessary.  
 The demographic table also demonstrates the clinical characteristics of the heart failure 
patients. The average triage systolic blood pressure was about 135mg of mercury; this is slightly above 
the normal 120. The average heart rate of enrolled heart failure patients was about 84 beats per 
minute, this within the normal range of 60-100 beats per minute. The average triage respiratory rate 
was about 22 breaths per minute, this is very high with the normal being approximately 12 breaths per 
minute.  This information is important in understanding the normal heart failure patient. From this we 
can see a trend that heart failure patients may present with an increase in respiratory rate and perhaps 
a slightly elevated systolic blood pressure. This is congruent with previous knowledge of how heart 
failure patients present. Tachycardia is typically also a symptom so the small sample size could be 
skewing the data down out of the tachycardia state.  
Another method of improving the efficiency of potential heart failure enrollment is to look at 
trends in the chief complaint of enrolled patients. Figure 12 shows the chief complaint of the 30 patients 
ruled into this clinical trial.  
 
Figure 12: Chief complaint of enrolled patients 
 As seen in Figure 12, twenty seven of the enrolled patients presented to the ED with dyspnea, 
which is shortness of breath, a common symptom of hear heart failure. This is congruent with the 
previous data showing that on average patients presented with an increased respiratory rate. There 
were a few patients who were enrolled with chest pain, peripheral edema and weakness and fatigue. As 
the study progresses the chief complaint of enrolled patients should be further investigated. It may be 
beneficial to enroll only patients who present with dyspnea or to at least limit enrollment to only include 
dyspnea, chest pain, peripheral edema and weakness. By limiting the symptoms of interest less time will 
be used investigating patient’s medical history before enrollment.  

























































































 When conducting this clinical trial doctors and residents were asked for their diagnostic 
impression of the patient before enrollment. Heart failure is a very difficult disease to diagnosis because 
the symptoms overlap with many other diseases.  The accuracy of the doctor’s initial diagnostic 
impression within the emergency department is examined in Figure 13.  
 
 
Figure 13: Diagnostic impression of patients within the ED 
 Figure 13 shows the diagnostic impression of the ED physician for all enrolled patients. The 
graph is further broken down into patients who were ruled into the study based upon the Framingham 
criteria. These data indicate that the doctors have been fairly accurate with their initial impression up 
until this point in the study.  Only one patient who was initially considered to be “likely” for heart failure 
was ruled out of the study. All patients who were enrolled that were considered to be unlikely or 
unclear for heart failure were ultimately ruled out by the Framingham criteria. Because heart failure is 
difficult to diagnosis there is some uncertainty when the initial diagnosis is considered to be possible.  
These data shows that investigators should respect the initial diagnosis of the emergency room doctor 
and only enroll patients who are considered to be likely or possible.  
4.2 Pre-Hospital Care 
The treatment the patient undergoes before entering the emergency room can help with the 
overall analysis of the patients’ treatment while in the hospital. Table 2 shows the mode of 
transportation to the ED and from there how many people received each type of medicine before 
entering the ED. There are 50 patients shown in the table but only 38 patients were enrolled during 











































































chart review. Many patients received some form of pre-hospital medicine. This will be looked at later to 
see if there was any effect on the administration of these drugs.  
 
Table 2: Pre-Hospital Care Demographics 
Mode of 
Transportation 
Pre-Hospital Meds Length of Stay 
Walk in EMS Home Ambulance Average 95.47 
21 29 Aspirin 10 Aspirin 3 Standard Deviation 84.11 
  Diuretics 8 Diuretics 2 Median 75.5 
  Nitrates 2 Nitrates 2   
  
During the course of treatment patients may be moved from the emergency department and 
admitted onto the floor or into the ICU. Typically patients who will be staying overnight are admitted 
onto the floor. Once on the floor, patients are given a room and are also reevaluated the next day by a 
specialist within cardiology.  Patients who are very ill and need direct and immediate care are admitted 
into the ICU. This is less frequent and represents the heart failure patients who had the most severe 
symptoms. Figure 14 presents the number of enrolled patients admitted in the ED, Floor and ICU during 
their visit.  
 
Figure 14: Patient admission data for enrolled patients 
 The graph in Figure 14 shows that of the 32 patients enrolled into the study 25 of the patients 
were admitted on the floor while only 3 were admitted into the ICU. Patients who were admitted into 
the ICU had the most severe symptoms, which may skew the results of this study. These data also 
demonstrate the level of hospital resources that are being used by heart failure patients.  Many patients 
who visit the emergency department receive treatment and are then discharged a few hours later. 
However, all of the heart failure patients enrolled into this study had been admitted onto the floor or 
ICU which is much more expensive for the hospital.  These resources might be saved if optimally 
effective and immediate care is given to heart failure patients within the emergency department.  
4.3 Symptom Improvement: Assessment of Common Medications 
To assess what the optimal car for these patients would be, the types of medications given 
within the emergency department were investigated. There are no set guidelines for the treatment of 
heart failure patients and therefore numerous types of medications are administered to these patients. 
Also, due to its overlap with other diseases, treatment for another disease may be given within the 
emergency room before the patient is diagnosed with heart failure.  Figure 15 shows the different types 
of medications that enrolled patients received during their emergency room visit.  
 
Figure 15: Medications administered in the ED 
 Figure 15 shows the variety of medications given to the enrolled heart failure patients. The most 
common three medications included loop diuretics, nitrates and aspirin. The effectiveness of these three 
medications was assessed during this clinical trail through the comparison of the short term outcomes 
among enrolled patients. Although this type of comparison will help determine which medication is the 
most effective, there are many confounding factors involved during a human study. Some patients will 
have less room for improvement due to mild initial symptoms, while others will present with severe 
symptoms initially. Also, some heart failure patients receive a panel of home medications. Due to these 
types of factors it will be difficult to see a significant correlation between any of these medications and 
short term outcomes with only a small sample size.  




















































































































4.4 Symptom Improvement: Assessment of blood pressure changes 
 Blood pressure changes are usually important characteristics for doctors to determine patient 
progress. In this study patient blood pressure is collected every hour for the first three hours of their 
emergency room visit. As patients progress during their stay their blood pressure should drop to within 
normal levels. Figure 16 shows a box and whisker plot of the change in systolic and diastolic blood 
pressure at each hour.  
 
Figure 16: Change in blood pressure after each hour of emergency room stay 
Figure 16 shows that there was a slight decrease in the average blood pressure throughout the 
emergency department visit of a patient. In this graph a decrease in blood pressure is marked as 
negative change while an increase in blood pressure is marked as positive change.  After the first hour in 
the emergency room both there were only small positive changes in systolic and diastolic blood 
pressure. After two hours the median change in blood pressure had moved into the negative region. 
This shows that patients were showing a decrease in blood pressure which is an indicator of symptom 
improvement.  After the third hour the median change in blood pressure was similar to the 2 hour data 
showing that the hospital may be stabilizing the patients once their blood pressure is slightly decreased. 
This graph also shows that there is a very large range for the change in blood pressures.  Some patients 
may have begun at much greater extremes and therefore they would have had more room for 
improvement. This data suggests that on average patients are improving throughout their stay within 
the emergency room. Blood pressure is an objective measure of symptom improvement and is more 
accurate than the overall well-being scales which rely on the opinion of the patient at a given time.  
4.5 Symptom Improvement: Assessment of length of Stay 
The length of stay associated with heart failure patients is a strong indicator of how the patient 
is doing. If patients stay longer, the hospital believes that they need to be in the hospital. Shortening 
length of stay could mean an increase in the patients’ health, as well as minimizing the cost to the 
hospital.   
The average length of hospital stay associated with heart failure patients was found to be 95.47 
hours with a standard deviation of 84.11. The median was found to be 75.5 showing that there were 
quite a few patients who stayed in the Emergency Department for an extended time which has the 
effect of increasing the average. 
Different medications are given for heart failure, so the question was does the timing of 
administration of these medicines reduce the length of stay. For this the medications were split into 
three categories, Aspirin, Diuretics and Nitrates. Each was examined based on the time that they were 
given, for example pre-hospital means given at home or in the ambulance. Whereas less than 1 hour 
means within an hour of arriving in the Emergency Department. Both refer to the patient having been 
given medicine both before arriving at the hospital and once in the Emergency Department. This is 
shown in Figure 17.  
 
Figure 17: Medications effects on length of stay 
 
In addition to the graphs an Analysis of Variance (ANOVA) was done for each medication. The 
ANOVA was done to see if there was significant difference in length of stay if medication was given 
versus if medication was not given. Table 3 shows the P values comparing weather each medication was 




Table 3: P values for the ANOVA of difference between medication given and medication not given on length of stay  





Figure 17a displays the data for length of stay based on when the patients received Aspirin. 
There is not an obvious trend affecting the length of stay, other than the people who were given pre-
hospital aspirin had the longest length of stay. However, the ANOVA gave a P value of 0.36 where 0.05 is 
significant. When generated this graph had extremely large error bars, which could attribute to the high 
P value.  The error bars make the large p value much less significant because it shows that the data was 
fairly inaccurate.  This shows that the time Aspirin is given or if it is given at all does not have a 
statistically significant affect the length of stay in patients presenting with heart failure. This is 
congruent with the knowledge that aspirin is typically used as a long term treatment for heart failure 
patients as well as for heart attacks.  
Figure 17B displays the data for length of stay for patients receiving diuretics. While the patients 
who were given diuretics prior to entering the emergency room appearing to have had a longer length 
of stay. This is possibly because the patients who are taking home medicines or who are given 
medication by EMS are the patients who are the most severe. In general, these patients likely have been 
diagnosed with heart failure before and know to take medicine before coming to the hospital. The other 
larger bar is the more than 3 hours, suggesting that the diuretic should be administered early in the 
emergency room stay.  
However, the ANOVA gave a P value of 0.72 where 0.05 is significant. This shows that there is no 
statistically significant difference if diuretic is given in the emergency department or not. This could 
mean that doctors are good at determining if a patient needs diuretics or not while in the emergency 
department. It is also possible that this is not correct since there was a very small sample of heart failure 
patients who did not receive diuretics. This small sample of patients may have been outliers and a larger 
sample size is needed to fully understand the effect of diuretics. 
 
Figure 17C demonstrates the trend in length of stay for patients receiving nitrates. The nitrates 
show a similar trend to the diuretics. Giving the patient nitrates in less than an hour after arriving in the 
emergency department may result in the shortest length of stay. The patients who were given nitrates 
both before entering the hospital and in the hospital appear to have had the longest length of stay. This 
may be the case because the patients who are given nitrates more than once are the patients who have 
the most severe symptoms and likely have been diagnosed with heart failure prior to this hospital stay.  
However, the ANOVA for nitrates given affecting length of stay gave a P value of 0.235. This is 
again; not significant meaning that statistically there is no difference in the length of stay for patients 
given nitrates compared to people not given nitrates. However, this is the closest to a significant P value 
out of the three medicines. This may be because there was more data for patients not given medication. 
The number of patients given nitrates was about equal to the amount of patients not given nitrates. This 
provides a much more accurate ANOVA than the other two medicines that had very small number of 
patients not given medicine.   
Overall we were unable to demonstrate that the medicines given in the emergency room affect 
the length of stay for patients with heart failure. Due to the small sample size it is hard to accept this as 
final conclusion. There are trends that one can see for diuretics and for nitrates that show giving the 
patient these medicines early may help to decrease the length of stay. There are also many other factors 
that play into the patient receiving these medications. Additionally some of these patients may be 
feeling better because they also receive other medications along with those examined here. 
4.6 Symptom Improvement: Assessment of patient Improvement  
In addition to studying the length of stay of the patients, the patient improvement was also 
examined based on how the patients say they feel.  Understanding how the patient responds to 
different medications depending on when they are given is important to understand the effects of 
medications. This is done by studying the 1 hour and the 3 hour global well being scale and comparing 
the difference between the two and the time medications was given. In the following graphs, the higher 
the bar the better the patient is feeling, or the most improvement was reported by the patient. The 
hypothesis is that the earlier the medication is given the better the patient will feel. This is shown in 
figure 18. 
 
Figure 18: Time medicine administered affecting patient improvement within 2 hours 
 As well as examining the graphs of times that the medications were given ANOVAs were done to 
see if there was a significant difference in patient perceived improvement between if medication was 
given compared to if medication was not given, the P values from here are shown in Table 4.  
Table 4: P values for the ANOVA of difference between medication given and medication not given on patient improvement 





The first medication examined was aspirin. The graphical representation shown in Figure 18A 
shows that the largest improvement was when aspirin is given in less than 1 hour. Aspirin could help the 
patient so that they are not in as much pain thus they believe they are doing better. The patients who 
were administered aspirin pre-hospital and the patients who were given medicine more than once could 
be those with the worst symptoms and, thus they were not feeling better in a short period of time.   The 
P value for this was 0.84, indicating that whether the patient receive aspirin or not does not affect the 
patient improvement.  
Figure 18B shows patient improvement based on the time that diuretics were given. The figure 
shows a trend that the more diuretics that are given as well as the earlier the diuretics are given the 
greater the patient perceived improvement was. This makes sense because the patient could have been 
feeling awful and the diuretics gave them a release of fluid. The more that is given and the more time it 
had to work would make the patient feel considerably better.  However, the P value obtained was 0.80, 
indicating there was no demonstrable difference in patient improvement with patients receiving 
diuretics and patients not receiving diuretics.  
Figure 18C examines patient improvement and time nitrates were administered. The figure 
shows the exact opposite of what was expected with the best patient improvement following 
administration more than 1 hour after arrival, and the least patient improvement being those receiving 
more than one dose of nitrates. The patients who received more than one dose of nitrates could be 
those with the worst pain resulting in their not feeling well regardless of medicine administered. The P 
value was found to be 0.80, again demonstrating no demonstrable   difference in patient improvement 
when patients received nitrates compared to when patients did not receive nitrates.  
Overall the data does not support the hypotheses. This is possibly because of the small sample 
size as well as the fact that the data is based on patient’s opinion. The patient often does not know what 
they marked previously so often times they are feeling much better but they mark the same spot as the 
1 hour mark or lower. There are also no hash marks defining 10, 20 and so on so it is hard for them to 
understand where they are placing their mark.  Because of all of this the results need to be reassessed 
when more patients have been enrolled. However, the visual analysis did show specific trends that the 
earlier the diuretics and nitrates were given the better the outcome for the patients. The aspirin had 
little effect because it is more of a long term treatment for heart failure patients and would not provide 
immediate relief.  Knowing this in the short term the researchers should continue to do as before while 
paying close attention to the diuretics and the nitrates, and the time they were administered.  
The P values compared patient improvement in regards to if medicine was administered or not 
so it is not surprising that they did not result in a significant difference. This could simply mean the 
doctors are good at determining when it is important to give these medications and when they are really 
not needed. This helps the patient and also saves the hospital time and money. 
4.7 Diuretic Use of Heart Failure Patients 
To gain a better understanding of why diuretics showed the strongest trend in length of stay and 
especially patient improvement within 2 hours the urine output that diuretics created was analyzed. The 
patients who were not given diuretics did not have recorded urine outputs. It was determined that the 
patients who received diuretics more than once had the greatest urine output, up to 1,525ml with a 
median of 1266. The other two patients approximately the same median of about 850ml. This shows 
that the use of diuretics helps to produce urine output which can alleviate the fluid that is built up in the 
body. This also shows that the more diuretic that is administered the more urine is produced. When 
comparing this to the patient improvement it appears that the greater the output of urine the more the 
patient feels improvement.  
4.8 Quality of Care 
Hospitals success depends on the care that they provide patients as well as the efficiency of the 
emergency room. If patients are unsatisfied with their care, their dissatisfaction can reflect poorly on 
the hospital. Many patients become irritated if they perceive   their stay in the emergency room was too 
long or they did not receive quality care.  
To assess the quality of care, the patients were asked how they would rate the quality of care as 
well as how satisfied they were with the care. Overall, the patients stated that the care they received in 
the emergency room was good, with 39% of patients indicating that the care was excellent, 33% very 
good and 28% good. The patients were generally satisfied, with 94% either very satisfied or satisfied and 
the rest unsure. Overall the patients reported that they received good care and were satisfied with that 
care.  
5. Major Conclusions and Recommendations  
 The enrollment criteria are the Framingham criteria. These criteria do have limitations, since it is 
not 100% accurate. It is possible that a patient does not have heart failure and then meet the 
requirements and it is also possible for a person with heart failure not to fit the criteria. The issue is that 
this criteria is known and accepted so despite the fact that it is not 100% accurate it is the best option to 
accurately identify heart failure patients.  
 The process of enrolling patients is important for the study, because enrolling the correct 
patients is crucial. Patients who aren’t in heart failure are not necessarily just thrown away they can be 
compared to the patients who did actually have heart failure. This can be useful to see how sometimes 
patients can be incorrectly identified and possibly why. This study showed that with the small sample 
size the patients are predominantly female, have dyspnea, and that the doctor is typically correct. At 
this time there is not a better way to enroll patients. Patients who are male or who do not present with 
one of the main chief complaints should not be overlooked. There are numerous ways that heart failure 
can present and to have the most accurate outcomes for the study all of these patients need to be 
studied. 
 There was a trend with nitrates and diuretics that show giving the patient these two 
medications early can decrease the length of stay; however, aspirin did not show that it mattered when 
it was administered. These trends hopefully will turn into actual concrete results when the sample size 
increases.  The patient improvement was seen mostly for diuretics when they were given a larger 
amount as well as when they were administered early. Aspirin also appeared to alleviate some of the 
patient’s distress resulting in an improvement in 2 hours. Nitrates, however, did not appear to have an 
effect on patient improvement.  
The P values were all not significant showing that if the patient received medicine or not did not 
affect their length of stay or as well as patient improvement. This could mean that the doctors in the 
emergency room are good at determining when they should and should not give medicine effectively 
saving the hospital time and money. The trends seem to show that it is important to the length of stay 
and patient improvement to give nitrates and diuretics early in the patients stay. Hopefully with further 
research it can be proven statistically.  
As the study progresses the major recommendations are that the research assistants continue 
to pay close attention to the Framingham criteria to enroll the patients. It is also recommended that the 
research assistants enroll as many patients who present with shortness of breath who are female. These 
patients should most defiantly be enrolled if a doctor finds it likely or highly likely that they have heart 
failure, since it was shown that the doctors are often correct with their diagnostic impressions.  The 
scales should also he altered. This could be something as simple as putting hash marks to identify a few 
numerical identifiers. This would help the patient understand a little better where they are marking the 
line on a scale of zero to 100. Another suggestion for the scales is that the patient is able to see their 
previous scales to allow them to remember what they had said as well as relate it to how they feel then 
to mark the appropriate value.    
These findings will hopefully allow for better patient care as well as save the hospital money by 
decreasing length of stay. The results as they are now do not necessarily have an effect on these things, 
but hopefully with a larger sample size the trends that were seen to reduce length of stay will turn into 
concrete results. The trend of administering medications within the first hour of treatment could really 
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